Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

Arcus Biosciences, Inc. Capital Expenditures

Arcus Biosciences, Inc. (RCUS) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05

  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.00M, a 0.00% change year-over-year.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $2.00M, a 66.67% decline from fiscal 2024.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $6.00M, a 75.00% decline from fiscal 2023.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $24.00M, a 300.00% increase from fiscal 2022.
  • Arcus Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $6.00M, a 76.92% decline from fiscal 2021.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 3 month as first filedPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 6 month as first filedPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 9 month as first filedPayments to Acquire Property, Plant, and Equipment 12 monthPayments to Acquire Property, Plant, and Equipment 12 month as first filed
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$0.00
10-Q · filed 2026-08-05
$1.00M
derived: sum of 3 quarters · filed 2026-08-05
$1.00M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$0.00
10-Q · filed 2026-05-05
$1.00M
derived: sum of 2 quarters · filed 2026-05-05
$1.00M
derived: sum of 3 quarters · filed 2026-05-05
$1.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$1.00M
derived: sum of 2 quarters · filed 2026-02-25
$1.00M
derived: sum of 3 quarters · filed 2026-08-05
$2.00M
10-K · filed 2026-02-25
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$0.00
derived: sum of 2 quarters · filed 2026-08-05
$1.00M
10-Q · filed 2025-10-28
$2.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$1.00M
10-Q · filed 2026-08-05
$2.00M
derived: sum of 3 quarters · filed 2026-08-05
$3.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$1.00M
10-Q · filed 2026-05-05
$2.00M
derived: sum of 2 quarters · filed 2026-05-05
$3.00M
derived: sum of 3 quarters · filed 2026-05-05
$3.00M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$2.00M
derived: sum of 2 quarters · filed 2026-02-25
$2.00M
derived: sum of 3 quarters · filed 2026-02-25
$6.00M
10-K · filed 2026-02-25
2024-09-30$1.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$1.00M
derived: sum of 2 quarters · filed 2025-10-28
$5.00M
10-Q · filed 2025-10-28
$11.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$4.00M
10-Q · filed 2025-08-06
$10.00M
derived: sum of 3 quarters · filed 2026-02-25
$20.00M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$4.00M
10-Q · filed 2025-05-06
$10.00M
derived: sum of 2 quarters · filed 2026-02-25
$20.00M
derived: sum of 3 quarters · filed 2026-02-25
$25.00M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$16.00M
derived: sum of 2 quarters · filed 2026-02-25
$21.00M
derived: sum of 3 quarters · filed 2026-02-25
$24.00M
10-K · filed 2026-02-25
2023-09-30$10.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$15.00M
derived: sum of 2 quarters · filed 2024-11-06
$18.00M
10-Q · filed 2024-11-06
$18.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30$5.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$8.00M
10-Q · filed 2024-08-08
$8.00M
derived: sum of 3 quarters · filed 2025-02-25
$10.00M
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31$3.00M
10-Q · filed 2024-05-08
$3.00M
derived: sum of 2 quarters · filed 2025-02-25
$5.00M
derived: sum of 3 quarters · filed 2025-02-25
$6.00M
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$2.00M
derived: sum of 2 quarters · filed 2025-02-25
$3.00M
derived: sum of 3 quarters · filed 2025-02-25
$6.00M
10-K · filed 2025-02-25
2022-09-30$2.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$3.00M
derived: sum of 2 quarters · filed 2023-11-07
$6.00M
10-Q · filed 2023-11-07
$5.62M
10-Q · filed 2022-11-02
$14.43M
derived: sum of 4 quarters · filed 2024-02-21
2022-06-30$1.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$4.00M
10-Q · filed 2023-08-07
$4.30M
10-Q · filed 2022-08-03
$12.43M
derived: sum of 3 quarters · filed 2024-02-21
$20.29M
derived: sum of 4 quarters · filed 2024-02-21
2022-03-31$3.00M
10-Q · filed 2023-05-09
$2.79M
10-Q · filed 2022-05-09
$11.43M
derived: sum of 2 quarters · filed 2024-02-21
$19.29M
derived: sum of 3 quarters · filed 2024-02-21
$25.36M
derived: sum of 4 quarters · filed 2024-02-21
2021-12-31$8.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21
$16.29M
derived: sum of 2 quarters · filed 2024-02-21
$22.36M
derived: sum of 3 quarters · filed 2024-02-21
$26.00M
10-K · filed 2024-02-21
$26.08M
10-K · filed 2022-02-23
2021-09-30$7.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$13.93M
derived: sum of 2 quarters · filed 2022-11-02
$17.57M
10-Q · filed 2022-11-02
$19.04M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$6.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$9.71M
10-Q · filed 2022-08-03
$11.18M
derived: sum of 3 quarters · filed 2023-02-28
$12.25M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$3.64M
10-Q · filed 2022-05-09
$5.11M
derived: sum of 2 quarters · filed 2023-02-28
$6.18M
derived: sum of 3 quarters · filed 2023-02-28
$6.43M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$1.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$2.54M
derived: sum of 2 quarters · filed 2023-02-28
$2.79M
derived: sum of 3 quarters · filed 2023-02-28
$3.00M
10-K · filed 2023-02-28
$3.06M
10-K · filed 2021-02-25
2020-09-30$1.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$1.33M
derived: sum of 2 quarters · filed 2021-11-08
$1.54M
10-Q · filed 2021-11-08
$1.73M
derived: sum of 4 quarters · filed 2022-02-23
2020-06-30$256.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$465.00K
10-Q · filed 2021-08-05
$661.00K
derived: sum of 3 quarters · filed 2022-02-23
$1.21M
derived: sum of 4 quarters · filed 2022-02-23
2020-03-31$209.00K
10-Q · filed 2021-05-05
$405.00K
derived: sum of 2 quarters · filed 2022-02-23
$955.00K
derived: sum of 3 quarters · filed 2022-02-23
$1.51M
derived: sum of 4 quarters · filed 2022-02-23
2019-12-31$196.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23
$746.00K
derived: sum of 2 quarters · filed 2022-02-23
$1.30M
derived: sum of 3 quarters · filed 2022-02-23
$1.93M
10-K · filed 2022-02-23
2019-09-30$550.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$1.10M
derived: sum of 2 quarters · filed 2020-11-05
$1.73M
10-Q · filed 2020-11-05
$1.99M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$551.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$1.18M
10-Q · filed 2020-08-06
$1.44M
derived: sum of 3 quarters · filed 2021-02-25
$2.56M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$628.00K
10-Q · filed 2020-05-05
$886.00K
derived: sum of 2 quarters · filed 2021-02-25
$2.01M
derived: sum of 3 quarters · filed 2021-02-25
$3.32M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$258.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$1.39M
derived: sum of 2 quarters · filed 2021-02-25
$2.69M
derived: sum of 3 quarters · filed 2021-02-25
$3.74M
10-K · filed 2021-02-25
2018-09-30$1.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$2.43M
derived: sum of 2 quarters · filed 2019-11-05
$3.48M
10-Q · filed 2019-11-05
$3.78M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30$1.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$2.36M
10-Q · filed 2019-08-06
$2.65M
derived: sum of 3 quarters · filed 2019-08-06
$3.49M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31$1.05M
10-Q · filed 2019-05-02
$1.35M
derived: sum of 2 quarters · filed 2019-05-02
$2.19M
derived: sum of 3 quarters · filed 2019-05-02
$4.43M
derived: sum of 4 quarters · filed 2019-05-02
2017-12-31$294.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05
$1.13M
derived: sum of 2 quarters · filed 2019-03-05
$3.38M
derived: sum of 3 quarters · filed 2019-03-05
$5.51M
10-K · filed 2019-03-05
2017-09-30$839.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$3.08M
derived: sum of 2 quarters · filed 2018-11-08
$5.22M
10-Q · filed 2018-11-08
2017-06-30$2.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06
$4.38M
10-Q · filed 2018-08-06
2017-03-31$2.14M
10-Q · filed 2018-05-09
2016-12-31$4.10M
10-K · filed 2019-03-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36